About 0xmd
0xmd develops medical AI and the applications that bring it into everyday care. It builds its own medical language and vision AI models and runs them on company-owned computing infrastructure. These models power a chat assistant, a health report reader, a food and medicine scanner, and imaging tools for clinicians, patients, teachers and researchers. Software agents pull medical records, read reports, build health profiles and weigh risk across several steps before combining the results into one answer. The imaging tool explains x-ray, MRI, CT and ECG terms and suggests questions for a doctor, but it does not diagnose.
0xmd is operated by its Hong Kong parent, 0x Limited, together with regional group companies: 0xmd Inc. in the United States and 0XMD LTDA in Brazil. In May 2025, it partnered with the Brazilian institution SENAI CIMATEC to begin operations in Brazil, after already working in the United States and China. Its product line includes Clinica for hospital records, a mobile health app, a telemedicine triage tool, a patient-simulation tool called Nooduo, and a tuberculosis-screening platform called TB-Guard.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Oct 28, 2026 | Nov 3, 2026 | $50,000of $1.0M target | 1 | $50,000 | EquityRule 506(c) | Form D ↗ |
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Why Investors Backed 0xmd
0xmd sells AI chat, scanning and imaging tools built on its own medical language and vision models. It serves patients, clinicians, researchers and educators through a web platform and a mobile app. 0xmd operates through a Hong Kong parent, 0x Limited, and a separate United States entity, 0xmd Inc. 0xmd Inc. notified regulators on November 3, 2026, after raising $50,000 from a single investor.
What the product does
0xmd's app offers a medical AI chat trained on medical literature, plus several scanning tools. A Food and Medicine Scan reads ingredient and medication labels. A Health Check Report Scan uses a vision AI tool to read health check reports and summarize key findings. A Skin Photo Guide and an Imaging tool explain what clinicians look for in skin concerns, X-rays, MRIs, CTs and ECGs, and suggest questions for a doctor. The company states that none of these tools make a diagnosis, and that the chat assistant supports more than 50 languages.
Progress so far
In May 2025, 0xmd announced a partnership with SENAI CIMATEC, a Brazilian technology and research institution, to start operations in Brazil. 0xmd already operated in the United States and China. The Brazil work started with automated clinical exam analysis, medical image interpretation and conversational diagnostic support. On November 3, 2026, 0xmd Inc. raised $50,000 from a single investor.
Who backs it
0xmd is operated by its Hong Kong parent, 0x Limited, together with group companies including 0xmd Inc. in the United States and 0XMD LTDA in Brazil. On November 3, 2026, 0xmd Inc. raised $50,000 from a single investor.
How the market is moving
0xmd's case is that demand for AI in health care is growing, especially for image-based diagnostics, clinical report automation and personalized therapies. It points to this demand as a reason for its move into Brazil.
We wrote this summary from public statements by 0xmd and its investors. It is not investment advice.
Leadership Team
Executive officers and directors listed on 0xmd's Form D filed Nov 3, 2026.